US 6,284,804 B1Grant

Topical suspension formulations containing ciprofloxacin and dexamethasone

Issue Date:2001-09-04

•1 Claims

Abstract

Suspension formulations containing dexamethasone and ciprofloxacin are disclosed. The formulations contain a nonionic polymer, a nonionic surfactant and an ionic tonicity agent, but are physically stable and easily re-suspended. The formulations are intended for topical application to the eye, ear or nose.

Metadata

Assignee

Alcon Universal Ltd.

Inventors

Onkar N. Singh
Haresh G. Bhagat

Application Information

Application Number:US 09/636,563

Filing Date:2000-08-10

Priority Date:1999-09-24

Art Unit:7

Classifications

IPC:

A61K 4732A61K 3174A61K 3156

Field of Search:

424 78424427424428424 855147724514912514169514171

Patent Drawings

This patent does not have any drawings.

Description

[0002] This application claims priority to co-pending U.S. Provisional Application, U.S. Ser. No. 60/155,942, filed Sep. 24, 1999.

BACKGROUND OF THE INVENTION

[0003] This invention relates to topically administrable ophthalmic and otic formulations of ciprofloxacin and dexamethasone. The formulations of the present invention are suspensions that have excellent physical stability and are characterized by their easy and ready resuspendibility. Specifically, the invention relates to stable suspension formulations of ciprofloxacin and dexamethasone that lack a nonionic tonicity agent, such as glycerol or mannitol.

[0004] Spanish Patent Application No. 2,065,846 A1 (Feb. 16, 1995) discloses topically administrable ophthalmic and otic antibiotic/steroid combination products. Examples 1-3 illustrate ophthalmic suspension formulations containing certain drug combinations with excipients including nonionic polymers and nonionic surfactants. Example 1 is a formulation of clobetasone and lomefloxacin that contains a nonionic tonicity agent (glycerin). Example 2 is a formulation of fluoromethalone and norfloxacin that contains an ionic tonicity agent (sodium chloride). Example 3 is a formulation of ciprofloxacin and dexamethasone that contains a nonionic tonicity agent (mannitol).

[0005] U.S. Pat. Nos. 5,540,930 and 5,747,061 disclose topically administrable steroid suspension formulations that contain a nonionic polymer, a nonionic surfactant and a nonionic tonicity agent. The patents are directed toward “stable suspensions of water-insoluble steroid drugs of particle sizes ≦15 μm, which remain in such a state so as to allow for immediate suspension, when desired, even after extended periods of settling” (see the '061 patent's Abstract). The patents are based on a finding that “[u]nexpectedly, common tonicity agents such as aqueous solutions containing 0.9% NaCI, 0.1% EDTA, or phosphate buffer, even in concentrations as low as 1 mM, can not be employed to provide stable aqueous suspensions of corticosteroids such as [loteprednol etabonate (LE)]” ('061 patent, Col. 2, lines 52-56).

[0006] The '061 patent is aimed at formulations that solved a need for “aqueous suspensions of corticosteroids such as LE which can be formulated without agglomeration” (Col. 2, lines 57-59). The '061 patent's formulations contain (A) a soft steroid such as LE present as particles preferably having a mean diameter of less than about 15 microns, (B) a nonionic polymer as a suspending agent, (C) a nonionic surfactant and (D) a nonionic tonicity agent. The '061 patent defines a “soft” drug as a biologically active chemical component characterized by predictable in vivo metabolism to non-toxic derivatives after it provides its therapeutic effect. The '061 patent teaches that “[i]t is essential that these components (A)-(D) be nonionic insofar as possible since it has now been discovered that the presence of ions is the major cause of caking” (Col. 3, lines 51-53). Nonionic diols such as glycerin or mannitol “rather than the commonly used sodium chloride” are identified as the preferred tonicity agents (see Col. 3, lines 53-56). The nonionic tonicity agent is preferably present in an amount of about 0.5 to 10% by weight.

SUMMARY OF THE INVENTION

[0007] Unless indicated otherwise, all ingredient amounts presented as a percentage are in units of weight %.

[0008] The compositions of the present invention are aqueous suspension formulations of corticosteroids (dexamethasone) that avoid agglomeration. In addition to a corticosteroid, these formulations include an antibiotic (ciprofloxacin) as a second active agent. The formulations of the present invention contain an ionic tonicity agent, but are nevertheless stable so as to be immediately and easily re-suspended when desired.

DETAILED DESCRIPTION OF THE INVENTION

[0009] The formulations of the present invention comprise a corticosteroid and an antibiotic. The corticosteroid is dexamethasone and the antibiotic is ciprofloxacin. Dexamethasone can be present in any ophthalmically or otically acceptable form having poor water solubility such that the resulting formulation is a suspension formulation. Suitable forms of dexamethasone include dexamethasone alcohol and dexamethasone acetate. Dexamethasone alcohol is the preferred form of dexamethasone. Ciprofloxacin can be present in any ophthalmically or otically acceptable form such that the ciprofloxacin ingredient is in solution in the final formulation. A preferred form of ciprofloxacin is ciprofloxacin hydrochloride, monohydrate.

[0010] The dexamethasone ingredient will comprise about 0.01-0.5% and the ciprofloxacin ingredient will comprise about 0.1-0.4% of the formulations of the present invention. The preferred amounts of dexamethasone and ciprofloxacin in the formulations of the present invention are 0.1% and 0.3%, respectively.

[0011] In addition to the active agents, the formulations of the present invention contain sodium chloride as an ionic tonicity agent. The amount of NaCI will depend on the desired tonicity for the final formulation, but will generally range from 0.1-0.9%. For ophthalmic and otic applications, the suspension formulations of the present invention preferably contain an amount of NaCI sufficient to cause the formulations to have an osmolality of about 250-350 mOsm.

[0012] The suspension formulations also contain a nonionic polymer. Many ophthalmically and otically acceptable nonionic polymers are known. These polymers include hydroxyethyl cellulose; hydroxypropylmethyl cellulose; methyl cellulose; carboxymethyl cellulose; polyvinyl pyrrolidone and polyvinyl alcohol. The preferred nonionic polymer is hydroxyethyl cellulose. The nonionic polymer will be present in the formulations of the present invention in an amount of about 0.1-0.5%. In the case of hydroxyethyl cellulose, the preferred concentration of nonionic polymer is 0.2%.

[0013] The formulations of the present invention also contain a nonionic surfactant in an amount from about 0.01-0.2%. Many ophthalmically and otically acceptable nonionic surfactants are known. Suitable nonionic surfactants include tyloxapol; polyoxyethylene sorbitan esters, such as polysorbate 20, polysorbate 60, and polysorbate 80; polyethoxylated castor oils, such as Cremaphor EL; polyethoxylated hydrogenated castor oils, such as HCO-40; and poloxamers. The preferred surfactant is tyloxapol.

[0014] If desired, the formulations may contain a quaternary ammonium halide as a preservative. Suitable quaternary ammonium halides include polyquaternium-1 and benzalkonium halides. Preferred benzalkonium halides are benzalkonium chloride (“BAC”) and benzalkonium bromide. In general, the amount of the preservative ingredient will range from about 0.005-0.3%. In the preferred case where the preservative is BAC, it is preferably present at a concentration of 0.01%.

[0015] If desired, a chelating agent may also be present in the suspension formulations of the present invention. Suitable chelating agents include edetate disodium (“EDTA”); edetate trisodium; edetate tetrasodium; and diethyleneamine pentaacetate. Most preferred is EDTA. The chelating agent, if any, will typically be present in an amount from about 0.001-0.1%. In the case of EDTA, the chelating agent is preferably present at a concentration of 0.01%.

[0016] In the case of preserved or multi-dose formulations, the suspension formulations of the present invention may contain boric acid in an amount from 0.1-1.5%.

[0017] The formulations of the present invention have a pH from 3-5, preferably 4.5. pH can be adjusted with NaOH/HCI. The preferred buffering system for the formulations is a combination of sodium acetate and acetic acid. The concentration of sodium acetate will generally range from 0.015-0.06%, and will preferably be about 0.03%. The concentration of acetic acid will generally range from 0.02-0.08, and will preferably be about 0.04%.

[0018] The average particle size (mean volume basis) of the dexamethasone ingredient should be less than 10 μm to avoid irritation or discomfort. The average particle size is preferably less than 6 μm and most preferably less than 3 μm. Dexamethasone particles can be sized using known techniques, such as ball-milling, microfluidization and sonication.

[0019] The suspension formulations of the present invention are intended for topical administration to the eye, ear or nose.

[0020] The following examples are intended to illustrate, but not limit, the present invention.

EXAMPLE 1

Formulation

[0021] Formulations A-E were made using the following method:

[0022] (1) For a formulation batch size of 500 ml, form a slurry by combining 75 g of 3 mm zirconium beads, 12 g of tyloxapol 1.0% stock solution and 0.5 g dexamethasone alcohol in a 30 ml polypropylene milling bottle (approx. 48% of the final batch requirement of tyloxapol is used);

[0023] (2) steam sterilize (autoclave) the slurry, including beads;

[0024] (3) aseptically ball mill the sterilized slurry for 18 hrs at 50 to 55 rpm;

[0025] (4) prepare an aqueous solution containing the remaining requirement of tyloxapol and the required amounts of all remaining ingredients (e.g., in the case of Formulation D, the remaining ingredients are ciprofloxacin hydrochloride monohydrate, benzalkonium chloride, sodium acetate, acetic acid, sodium chloride, hydroxyethylcellulose, boric acid, edetate disodium, and purified water;

[0026] (5) steam sterilize (autoclave) the aqueous solution prepared in step (4);

[0027] (6) combine the sterile slurry obtained in step 3 to the sterile solution obtained in step 5 by aseptically pouring the slurry through a sterile sieve (to remove the beads) into the solution obtained in step 5;

[0028] (7) adjust the formulation weight to 80-90% of batch weight using sterile-filtered purified water;

[0029] (8) check the final pH and adjust to pH 4.5±0.2 by sterile-filtered sodium hydroxide or hydrochloric acid, if needed; and

[0030] (9) bring the formulation to 100% of batch weight using sterile-filtered purified water.

[0031] An alternative method of preparing Formulations A-E, especially when the dexamethasone raw material is supplied or available already meeting the desired particle size specifications, is as follows:

[0032] (1) dry heat sterilize the dexamethasone raw material (recommended specification: between 7-11 hrs. at 130-140° C. (internal powder temperature);

[0033] (2) prepare a tyloxapol solution containing the batch requirement of tyloxapol in purified water;

[0034] (3) sterilize the tyloxapol solution by passing it through a 0.2 μm filter;

[0035] (4) aseptically combine the sterilized dexamethasone with the sterilized tyloxapol solution to form a sterile slurry and stir until homogenous;

[0036] (5) prepare an aqueous solution containing the required amounts of the remaining ingredients (e.g., in the case of Formulation D, the remaining ingredients are ciprofloxacin hydrochloride, monohydrate benzalkonium chloride, sodium acetate, acetic acid, sodium chloride, hydroxyethylcellulose, boric acid, edetate disodium and purified water;

[0037] (6) steam sterilize (autoclave) the aqueous solution prepared in step (5);

[0038] (7) aseptically combine the sterile slurry prepared in step (4) with the sterilized solution prepared in step (6);

[0039] (8) adjust the formulation weight to 80-90% of batch weight using sterile-filtered, purified water.

[0040] (9) check the final pH and adjust to pH 4.5±0.2 by sterile-filtered sodium hydroxide or hydrochloric acid, if needed; and

[0041] (10) bring the formulation to 100% of batch weight using sterile-filtered purified water.

EXAMPLE 2

[0042] Formulations A-E were tested for resuspension time in “accelerated” and “real-time” settling studies.

[0043] Accelerated settling studies were performed by subjecting 5 g of each formulation in a separate 16×125 mm flat-bottom glass tube to centrifugation for 30 minutes at 3100 rpm using an IEC CENTRA-7 centrifuge. The resuspendability of the settled material is tested by measuring the number of seconds of wrist shaking required to fully re-suspend the sediment.

[0044] Real time settling studies were performed by allowing 5 g of each Formulation in 16×125 mm flat-bottom glass tubes to undergo natural settling (under gravity) for seven days (except Formulation B, which was tested after four days). The resuspendability of the settled material is tested by measuring the number of inversions required to fully re-suspend the sediment. Table 2 contains the resuspendability results of the tested formulations.

EXAMPLE 3

Preservative Effectiveness Test

[0045] The antimaicrobial effectiveness of the polymeric quaternary ammonium compound/boric acid combination of the present invention was determined using an organism challenge test according to the methods described in the United States Pharmacopeia (USP) and European Pharmacopia (Ph. Eur.). Samples were inoculated with known levels of gram-positive (Staphylococcus aureusATCC 6538) and gram-negative (Pseudomonas aeruginosaATCC 9027 and Escherichia coliATCC 8739) vegetative bacteria, yeast (Candida albicansATCC 10231) and mold (Aspergillus nigerATCC 16404) and sampled at specified intervals to determine if the antimicrobial preservative sistem was capable of killing or inhibiting the propagation of organisms purposely ointroduced into the formulation. The rate or level of antimicrobial activity determined compliance with the USP and/or Ph. Eur. preservative efficacy standard for ophthalmic preparations.

[0046] The requirements of compendial preservative standards for ophthalmic preparations are presented below:

For Bacteria

[0047] (Staphylococcus aureus, Pseudomonas aeruginosa and Escherichia coli)

[0048] The results of the preservative challenge study conducted on the formulations of Examples 1-4 are shown in Table 3. These results illustrate that, if desired, the suspension formulation of the present invention can be preserved such that it meets both the United States Pharmacopoeia (USP) and European Pharmacopoeia (Ph. Eur.) minimum preservative requirements for ophthalmic and otic formulations.

[0049] Each of the Formulations listed in Table 3 passed Ph. Eur. A preservation criteria against bacteria and Candida albicans, but formulations lacking boric acid had difficulty passing Ph. Eur. B preservation criteria against Aspergillus niger. The combination of boric acid and benzalkonium chloride improved the preservative activity against Aspergillus nigerand formulation easily met Ph. Eur. B preservative effectiveness criteria. Formulation B (without boric acid) met only USP criteria and failed the minimum Ph. Eur. Preservation requirements. Formulation C (without boric acid) met USP and Ph. Eur. B (minimum) requirements. Formulation A initially met Ph. Eur. B requirements, but showed decreased activity against Aspergiflus nigerwhen re-tested at 52 weeks. Initial and 52-week results for Formulation A are shown in Table 4.

[0050] The invention has been described by reference to certain preferred embodiments; however, it should be understood that it may be embodied in other specific forms or variations thereof without departing from its spirit or essential characteristics. The embodiments described above are therefore considered to be illustrative in all respects and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description.

Claims

Certificate of Correction present

The claims shown below may not include correction changes. Use the corrected PDF for authoritative text.

What is claimed is:

1. A topically administrable suspension composition intended for application to the eye, ear or nose consisting essentially of

wherein the composition has a pH of 4.5±0.2.

a) 0.1% (wt.) dexamethasone alcohol;

b) 0.35% (wt.) ciprofloxacin hydrochloride, monohydrate;

c) NaCI in an amount sufficient to cause the composition to have an osmolality of about 250-350 mOsm;

d) 0.2% (wt.) hydroxyethyl cellulose;

e) 0.05% (wt.) tyloxapol;

f) a buffer comprising sodium acetate and acetic acid;

g) 0.01% (wt.) benzalkonium chloride;

h) 0.01% (wt.) edetate disodium;

i) 0.6% (wt.) boric acid; and

Patent Citations (20)

Patent	Date	Inventor	Cited By
US3134718	1964-05-01	Nobile	Applicant
US4670444	1987-06-01	Grohe et al.	Applicant
US4686214	1987-08-01	Boltralik	Applicant
US4844902	1989-07-01	Grohe	Applicant
US5223493	1993-06-01	Boltralik	Applicant
US5420120	1995-05-01	Boltralik	Applicant
US5540930	1996-07-01	Guy et al.	Applicant
US5679336	1997-10-01	Ali et al.	Applicant
US5747061	1998-05-01	Amselem et al.	Applicant
US5843930	1998-12-01	Purwar et al.	Applicant
US5863841	1999-01-01	Liedtke	Applicant
EP661055A1	1995-07-01		Applicant
EP868919A2	1998-10-01		Applicant
ES2065846	1995-08-01		Applicant
WO-90/01933	1990-03-01		Examiner
WO90/01933	1990-03-01		Applicant
WO/18387	2000-04-01		Applicant
WO/18388	2000-04-01		Applicant
WO/18404	2000-04-01		Applicant
WO/18386	2000-04-01		Applicant

Non-Patent Literature (9)

Product Insert for Vexol® 1% (Rimexolone Ophthalmic Suspension).Applicant
Engel et al., “Effectiveness of Specific Antibiotic/Steroid Combinations for Therapy of Experimental Pseudomonas aeruginosa Keratitis,” Current Eye Research, pp. 229-234 (1994).Applicant
Hobden et al., “Ciprofloxacin and Prednisolone Therapy for Experimental Pseudomonas Keratitis,” Current Eye Research, vol. 11(3), pp. 259-266 (1992).Applicant
Hobden et al., “Prednisolone Acetate or Prednisolone Phosphate Concurrently Administered With Ciprofloxacin for the Therapy of Experimental Pseudomonas Aeruginosa Keratitis,” Current Eye Research, vol. 12(5), pp. 469-473 (1993).Applicant
“Biamotil-D” Product Insert.Applicant
“Steroid and Antibiotic Solutions and Suspensions,” Ophthalmic Drug Facts 1999, pp. 121-122 (1999).Applicant
Doshi et al., “Preparation and Evaluatio of New Eye-Drops Containing a Combination of Ciprofloxacin and Dexamethasone,″”Indian Drugs, vol. 37(4); pp. 190-195 (2000).Applicant
Sucker et al., “Pharmazeutische Technologie,” Thieme Verlag, pp. 643-661 (1992).Applicant
Ciloxan® Product Information, Physicians′ Desk Reference for Ophthalmology, pp. 209-211 (1998).Applicant

Abstract